The world’s biggest maker of generic drugs is looking for a new CEO to oversee one of the toughest turnaround jobs in the industry.
The only thing that probably won’t be big about the role is the pay: Teva Pharmaceutical Industries Ltd.’s outgoing chief executive officer, Erez Vigodman, earned $5.7 million in 2015, making him the second-lowest paid CEO among rivals tracked by Bloomberg with at least $20 billion market value.
Vigodman’s successor has ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.